Tag: XALKORI

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to XALKORI

US FDA Expands Approval of Pfizer's LORBRENA® as First-Line Treatment for ALK-Positive ...

Added to Collection on: 2021-03-04 00:00:00

Tags for this article:

Chemical compounds
Organic compounds
Piperidines
Breakthrough therapy
Protein kinase inhibitors
Tyrosine kinase receptors
Lung cancer
Lorlatinib
ALK inhibitor
Ceritinib
Anaplastic lymphoma kinase
ROS1
XALKORI
Pfizer Inc.
Alectinib
u.s. food and drug administration

Click the tags to see associated articles and topics

View Article Details
U.S. FDA Expands Approval of Pfizer's LORBRENA® as First-Line Treatment for ALK-Positive ...

Added to Collection on: 2021-03-04 14:44:28

Tags for this article:

Chemical compounds
Organic compounds
Piperidines
Breakthrough therapy
Protein kinase inhibitors
Tyrosine kinase receptors
Lung cancer
Lorlatinib
Ceritinib
ALK inhibitor
Anaplastic lymphoma kinase
ROS1
XALKORI
Pfizer Inc.
Alectinib
u.s. food and drug administration

Click the tags to see associated articles and topics

View Article Details
Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda

Added to Collection on: 2021-03-04 15:45:00

Tags for this article:

Chemical compounds
Piperidines
Organic compounds
Chemistry
Protein kinase inhibitors
Breakthrough therapy
Orphan drugs
Lung cancer
Ceritinib
Crizotinib
ALK inhibitor
Anaplastic lymphoma kinase
Pfizer
XALKORI
Lorbrena
PFIZER'S

Click the tags to see associated articles and topics

View Article Details
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK ...

Added to Collection on: 2022-01-30 10:05:42

Tags for this article:

Chemical compounds
Organic compounds
Aromatic compounds
Breakthrough therapy
Tyrosine kinase receptors
Lung cancer
Piperidines
Orphan drugs
ALK inhibitor
Anaplastic lymphoma kinase
Ceritinib
Lorlatinib
XALKORI
I Pfizer Inc.

Click the tags to see associated articles and topics

View Article Details
Pfizer's Lorbrena shows PFS improvement in Phase III lung cancer trial

Added to Collection on: 2022-04-11 14:12:56

Tags for this article:

Chemical compounds
Organic compounds
Aromatic compounds
Lung cancer
Tyrosine kinase receptors
Piperidines
ALK inhibitor
Orphan drugs
Anaplastic lymphoma kinase
Crizotinib
Lorlatinib
Non-small-cell lung carcinoma
XALKORI
pfizer global

Click the tags to see associated articles and topics

View Article Details